We report the design and synthesis of novel prostaglandin-ethanolamide (PGE2-EA) analogs containing head and tail group modifications to aid in the characterization of a putative prostamide receptor(s). Our synthetic approach utilizes Horner-Wadsworth-Emmons and Wittig reactions to construct the head and the tail moieties of the key PGE2 precursor, which leads to the final products through a peptide coupling, Swern oxidation and HF/pyridine assisted desilylation. The synthesized analogs were shown not to interact significantly with endocannabinoid proteins and recombinant EP1, EP3 and EP4 receptors and suggest a yet to be identified prostamide receptor as their site(s) of action.
Finnegan, David F.,Shelnut, Erin L.,Nikas, Spyros P.,Chiang, Nan,Serhan, Charles N.,Makriyannis, Alexandros
supporting information
p. 1228 - 1231
(2015/04/13)
PROCESS FOR THE PREPARATION OF PROSTAGLANDIN DERIVATIVES
The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use in the preparation of prostaglandin derivatives.Said process comprises: a) reacting compounds of formula (I) with compounds of formula (II) to give compounds of formula (III) b) reducing with an asymmetric reducing agent the oxo group of the side chain of compounds of formula (III) to give compounds of formula (IV)
-
Page/Page column 15-16
(2010/09/17)
More Articles about upstream products of 1240483-13-9
Get Best Price for1240483-13-9(3aR,4R,5R,6aS)-5-((tert-butyldimethylsilyl)oxy)-4-((E)-3-oxo-5-phenylpent-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-one